RT Journal Article
SR Electronic
T1 <sup>89</sup>Zr-Bevacizumab PET Imaging in Primary Breast Cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1014
OP 1018
DO 10.2967/jnumed.112.117218
VO 54
IS 7
A1 Gaykema, Sietske B.M.
A1 Brouwers, Adrienne H.
A1 Lub-de Hooge, Marjolijn N.
A1 Pleijhuis, Rick G.
A1 Timmer-Bosscha, Hetty
A1 Pot, Linda
A1 van Dam, Gooitzen M.
A1 van der Meulen, Sibylle B.
A1 de Jong, Johan R.
A1 Bart, Joost
A1 de Vries, Jakob
A1 Jansen, Liesbeth
A1 de Vries, Elisabeth G.E.
A1 Schröder, Carolien P.
YR 2013
UL http://jnm.snmjournals.org/content/54/7/1014.abstract
AB Vascular endothelial growth factor (VEGF)-A is overexpressed in most malignant and premalignant breast lesions. VEGF-A can be visualized noninvasively with PET imaging and using the tracer 89Zr-labeled bevacizumab. In this clinical feasibility study, we assessed whether VEGF-A in primary breast cancer can be visualized by 89Zr-bevacizumab PET. Methods: Before surgery, breast cancer patients underwent a PET/CT scan of the breasts and axillary regions 4 d after intravenous administration of 37 MBq of 89Zr-bevacizumab per 5 mg. PET images were compared with standard imaging modalities. 89Zr-bevacizumab uptake was quantified as the maximum standardized uptake value (SUVmax). VEGF-A levels in tumor and normal breast tissues were assessed with enzyme-linked immunosorbent assay. Data are presented as mean ± SD. Results: Twenty-five of 26 breast tumors (mean size ± SD, 25.1 ± 19.8 mm; range, 4–80 mm) in 23 patients were visualized. SUVmax was higher in tumors (1.85 ± 1.22; range, 0.52–5.64) than in normal breasts (0.59 ± 0.37; range, 0.27–1.69; P &lt; 0.001). The only tumor not detected on PET was 10 mm in diameter. Lymph node metastases were present in 10 axillary regions; 4 could be detected with PET (SUVmax, 2.66 ± 2.03; range, 1.32–5.68). VEGF-A levels in the 17 assessable tumors were higher than in normal breast tissue in all cases (VEGF-A/mg protein, 184 ± 169 pg vs. 10 ± 21 pg; P = 0.001), whereas 89Zr-bevacizumab tumor uptake correlated with VEGF-A tumor levels (r = 0.49). Conclusion: VEGF-A in primary breast cancer can be visualized by means of 89Zr-bevacizumab PET.